SCHEMBL175260

SCHEMBL175260

C=CCn1cc[nH]c1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13072244 0.81
SCHEMBL3576045 0.75 ALDH1A1 (0.39)
SCHEMBL4537742 0.72 DUT (0.49)
SCHEMBL6675403 0.70 CYP3A4 (0.52)
SCHEMBL3629435 0.70 ALDH1A1 (0.43)
SCHEMBL4448355 0.68
SCHEMBL128380 0.68 CYP3A4 (0.45)
SCHEMBL3425729 0.67
SCHEMBL13584600 0.65 KMT2A (0.40)
SCHEMBL18097097 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3193849-A1 OPIPRAMOL PATCH Neuroderm, Ltd. (IL) 2017-07-26 EP claimed
WO-2016042413-A1 OPIPRAMOL PATCH NEURODERM, LTD. (IL) 2016-03-24 WO claimed
US-7879344-B2 contains antiitch agent; for use in wipes and absorbent articles, and transdermal patches KIMBERLY-CLARK WORLDWIDE, INC. (US) 2011-02-01 US claimed
EP-2040693-A2 TRANSDERMAL DELIVERY OF OLEOCANTHAL FOR RELIEF OF INFLAMMATION Kimberly-Clark Worldwide, Inc. (US) 2009-04-01 EP claimed
US-20080003273-A1 Transdermal Delivery of Oleocanthal for Relief of Inflammation KIMBERLY-CLARK WORLDWIDE, INC. (US) 2008-01-03 US claimed
WO-2008001240-A2 TRANSDERMAL DELIVERY OF OLEOCANTHAL FOR RELIEF OF INFLAMMATION KIMBERLY-CLARK WORLDWIDE, INC. (US) 2008-01-03 WO claimed
EP-0813879-B1 Drug administration composition for iontophoresis HISAMITSU PHARMACEUTICAL CO (JP) 2002-10-30 EP claimed
US-20240180922-A1 TREATMENTS FOR DIABETIC NEUROPATHY UNIV MANITOBA (CA) 2024-06-06 US disclosed
US-20240166596-A1 SULFAMOYL BENZENE DERIVATIVES AND USES THEREOF APHIOTX INC (CA) 2024-05-23 US disclosed
EP-4370502-A1 SULFAMOYL BENZENE DERIVATIVES AND USES THEREOF AphioTx Inc. (CA) 2024-05-22 EP disclosed
US-20240108648-A1 STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS ADORA LIFE SCIENCE, INC. 2024-04-04 US disclosed
WO-2024072942-A2 SKIN PENETRATING FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS ADORA ANIMAL HEALTH CORPORATION (US) 2024-04-04 WO disclosed
EP-4333802-A1 WOUND TREATMENT COMPOSITION CS Medica A/S (DK) 2024-03-13 EP disclosed
EP-0989845-A1 TOPICAL ADMINISTRATION OF CATECHOLAMINES AND RELATED COMPOUNDS TO SUBCUTANEOUS MUSCLE TISSUE USING PERCUTANEOUS PENETRATION ENHANCERS PERRICONE, Nicholas V (US) 2000-04-05 EP disclosed
US-5908400-A DRUG DELIVERY HISAMITSU PHARMACEUTICAL CO., INC. (JP) 1999-06-01 US disclosed
US-5879690-A Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers N.V. PERRICONE LLC 1999-03-09 US disclosed
WO-1998050014-A1 TOPICAL ADMINISTRATION OF CATECHOLAMINES AND RELATED COMPOUNDS TO SUBCUTANEOUS MUSCLE TISSUE USING PERCUTANEOUS PENETRATION ENHANCERS PERRICONE NICHOLAS V (US) 1998-11-12 WO disclosed
EP-0813887-A2 A device structure for iontophoresis HISAMITSU PHARMACEUTICAL CO. INC. (JP) 1997-12-29 EP disclosed
EP-0813879-A2 Drug administration composition for iontophoresis HISAMITSU PHARMACEUTICAL CO. INC. (JP) 1997-12-29 EP disclosed
US-4845233-A TOPICAL PENETRATION ENHANCER FOR PHYSIOLOGICALLY ACTIVE AGENTS IPRX, INC. (US) 1989-07-04 US disclosed